greeksoup/ stock research

SBC Medical Group Holdings Inc.: Q3 FY2026 earnings call

What management said about Q3 FY2026, from the documents filed with the SEC on 13 November 2026: press release. The quarter’s numbers.

Key takeaways

  • Revenue rose 35% in the quarter: Quarterly revenue was $59 million, up 35% year-over-year. Source
  • Operating income rose 66%: Income from operations was $26 million, with a 45% operating margin, compared with $15.9 million a year earlier. Source
  • Clinic network reached 293 locations: The clinic network had 293 locations at September 30, 2026, up 36 year-over-year across the support and partnership network. Source
  • Net income margin fell to 27%: Net income margin was 27%, against 30% a year earlier. The nine-month net income margin was 25%, against 27%. Source
  • Adjusted EBITDA margin rose to 47%: Adjusted EBITDA was $28 million, up 66%. Adjusted EBITDA is a non-GAAP measure, reconciled to net income in the release. Source
  • Operating cash flow reached $50 million: Nine-month operating cash flow was $50 million, compared with an outflow of $27 million in the same period of 2025. Source
  • Cash and Net Cash reported: Cash and cash equivalents were $198 million and Net Cash was $154 million. Net Cash, a non-GAAP measure, deducts borrowings and lease liabilities from cash. Source

“Our goal is not simply to add locations. We aim to raise productivity and profitability at the clinics we support while expanding the network efficiently.”

Yoshiyuki Aikawa, Chairman and CEO

Guidance

AreaPeriodFigureAgainst last quarter
Service feesFull year, if impact is realized for a full yearapproximately $15 million annually (converted at ¥158.1/US$)

What changed from last quarter

  • New: Consolidation of Waqoo is cited as a contributor to revenue growth. The previous release did not mention Waqoo. Source

Results and growth drivers

  • Revenue rose 35% in the quarter: Quarterly revenue was $59 million, up 35% year-over-year. Source
  • Operating income rose 66%: Income from operations was $26 million, with a 45% operating margin, compared with $15.9 million a year earlier. Source
  • Net income attributable rose 22%: Net income attributable to SBC Medical was $16 million, up 22%. Basic EPS was $0.15, up 25% from $0.12. Source
  • Nine-month revenue rose 13%: Nine-month revenues were $151 million, up 13% from $134 million. Nine-month net income attributable to SBC Medical was $38 million, up 2%. Source
  • Fee revisions and new clinics cited: Management credited previously announced service fee revisions and new clinic openings for revenue growth and operating margin improvement. Source

Clinic network and patient volumes

  • Clinic network reached 293 locations: The clinic network had 293 locations at September 30, 2026, up 36 year-over-year across the support and partnership network. Source
  • Patient visits rose 9%: Trailing twelve-month patient visits totaled 7.06 million, up 9% year-over-year. Source
  • Spend per visit rose 4%: Average spend per visit rose to $290, up 4% year-over-year. Source
  • Network and service fees as two levers: Management named two levers for MSO revenue growth, expanding the clinic network and increasing service fees per clinic, with a stated aim of raising productivity. Source

“We intend to deploy this strong financial position toward disciplined growth investment, with the goal of sustaining EPS growth over the medium- to long-term and enhancing corporate value.”

Yoshiyuki Aikawa, Chairman and CEO

Margins and costs

  • Net income margin fell to 27%: Net income margin was 27%, against 30% a year earlier. The nine-month net income margin was 25%, against 27%. Source
  • Adjusted EBITDA margin rose to 47%: Adjusted EBITDA was $28 million, up 66%. Adjusted EBITDA is a non-GAAP measure, reconciled to net income in the release. Source
  • Cost of revenues and SG&A increased: Cost of revenues was $16.4 million, against $12.7 million a year earlier. Selling, general and administrative expenses were $15.8 million, against $14.7 million. Source

Cash, capital and shareholder returns

  • Operating cash flow reached $50 million: Nine-month operating cash flow was $50 million, compared with an outflow of $27 million in the same period of 2025. Source
  • Cash and Net Cash reported: Cash and cash equivalents were $198 million and Net Cash was $154 million. Net Cash, a non-GAAP measure, deducts borrowings and lease liabilities from cash. Source
  • Bank repayments rose sharply: Nine-month repayments of bank and other borrowings were $8.9 million, against $0.7 million a year earlier. Source
  • No buybacks in nine months: Shares outstanding stayed at 102,576,943. No repurchases occurred in the first nine months of 2026, against $5.0 million in the prior-year period. Source

AI and technology investment

  • Proprietary local LLM under development: Management is building a proprietary local large language model infrastructure for secure use of medical data while managing AI costs. Source
  • Atomic Software alliance for clinic systems: A capital and business alliance with Atomic Software is advancing clinic operating systems. Source
  • AI investment aimed at clinic profitability: Management said these initiatives are intended to lift profitability at existing clinics and make new clinic openings more efficient. Source

Longevity, Japan and international growth

  • Longevity starts with DNA test: Longevity work begins with an in-house DNA methylation test for biological age, intended to link testing, personalized treatment and outcome evaluation. Source
  • Japan aesthetic and non-aesthetic plans: Management plans to keep expanding multi-brand aesthetic dermatology in Japan and to widen non-aesthetic medical services. Source
  • International push with OrangeTwist and ASEAN: Internationally, management is pursuing collaboration with OrangeTwist in the United States and expansion across ASEAN markets. Source

Figures management reported

FigureReported
Clinic locations Source293, up 36 year-over-year
Patient visits (trailing twelve months) Source7.06 million, up 9%
Average spend per visit Source$290, up 4%

Earlier plans management reported on

  • Met: Management says the 2025 structural reforms are implemented and that growth and profitability are improving together. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.